469 related articles for article (PubMed ID: 24373081)
1. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
2. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Asselah T; Marcellin P
Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
[TBL] [Abstract][Full Text] [Related]
3. Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
Abdel-Razek W; Waked I
Liver Int; 2015 Jan; 35 Suppl 1():27-34. PubMed ID: 25529085
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
5. [New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Horváth G; Halász T; Makara M; Hunyady B
Orv Hetil; 2015 May; 156(21):841-8. PubMed ID: 26038991
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Welch NM; Jensen DM
Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
[TBL] [Abstract][Full Text] [Related]
7. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Serfaty L
Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
9. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
10. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Hill A; Khoo S; Fortunak J; Simmons B; Ford N
Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
12. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.
Barreiro P; Vispo E; Poveda E; Fernández-Montero JV; Soriano V
Clin Infect Dis; 2013 Feb; 56(4):560-6. PubMed ID: 23090932
[TBL] [Abstract][Full Text] [Related]
14. HCV F1/F2 patients: treat now or continue to wait.
Shiffman ML; Benhamou Y
Liver Int; 2014 Feb; 34 Suppl 1():79-84. PubMed ID: 24373082
[TBL] [Abstract][Full Text] [Related]
15. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
16. Management of HCV patients with cirrhosis with direct acting antivirals.
Boccaccio V; Bruno S
Liver Int; 2014 Feb; 34 Suppl 1():38-45. PubMed ID: 24373077
[TBL] [Abstract][Full Text] [Related]
17. Faldaprevir for the treatment of hepatitis C.
Kanda T; Yokosuka O; Omata M
Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
[TBL] [Abstract][Full Text] [Related]
18. Emerging treatments for hepatitis C.
Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
[TBL] [Abstract][Full Text] [Related]
19. HCV NS5A inhibitors in development.
Suk-Fong Lok A
Clin Liver Dis; 2013 Feb; 17(1):111-21. PubMed ID: 23177287
[TBL] [Abstract][Full Text] [Related]
20. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]